These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 19061152)

  • 1. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
    Pistrosch F; Schaper F; Passauer J; Koehler C; Bornstein SR; Hanefeld M
    Horm Metab Res; 2009 Feb; 41(2):104-8. PubMed ID: 19061152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes.
    Ogawa S; Takeuchi K; Ito S
    Diabetes Obes Metab; 2004 Sep; 6(5):384-90. PubMed ID: 15287932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose].
    Gentile S; Turco S; Guarino G; Oliviero B; Rustici A; Torella R
    Ann Ital Med Int; 1999; 14(1):7-14. PubMed ID: 10528419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The alpha-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes.
    Hasegawa G; Kajiyama S; Tanaka T; Imai S; Kozai H; Fujinami A; Ohta M; Obayashi H; Park H; Nakano K; Tanaka M; Shiraishi E; Fukui M; Yoshikawa T; Nakamura N
    Clin Chim Acta; 2008 Apr; 390(1-2):110-4. PubMed ID: 18230353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation.
    Azuma K; Toyofuku Y; Iesaki T; Otsuka A; Tanaka A; Mita T; Hirose T; Tanaka Y; Daida H; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2006 Jun; 345(2):688-93. PubMed ID: 16696939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
    Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
    Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
    Chang AM; Smith MJ; Bloem CJ; Galecki AT; Halter JB
    Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E906-11. PubMed ID: 15213063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
    Sieradzki J; Soszyński P
    Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study.
    Shimabukuro M; Higa N; Chinen I; Yamakawa K; Takasu N
    J Clin Endocrinol Metab; 2006 Mar; 91(3):837-42. PubMed ID: 16368744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
    García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
    Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
    Arakawa M; Ebato C; Mita T; Fujitani Y; Shimizu T; Watada H; Kawamori R; Hirose T
    Metabolism; 2008 Sep; 57(9):1299-306. PubMed ID: 18702958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients.
    Scognamiglio R; Negut C; De Kreutzenberg SV; Tiengo A; Avogaro A
    Circulation; 2005 Jul; 112(2):179-84. PubMed ID: 15998667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs.
    Rudofsky G; Reismann P; Schiekofer S; Petrov D; von Eynatten M; Humpert PM; Isermann B; Müller-Hoff C; Thai TP; Lichtenstein S; Bärtsch U; Hamann A; Nawroth P; Bierhaus A
    Horm Metab Res; 2004 Sep; 36(9):630-8. PubMed ID: 15486815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls.
    Neri S; Signorelli SS; Torrisi B; Pulvirenti D; Mauceri B; Abate G; Ignaccolo L; Bordonaro F; Cilio D; Calvagno S; Leotta C
    Clin Ther; 2005 Nov; 27(11):1764-73. PubMed ID: 16368447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
    Sakamoto N; Tajima N
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U
    Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antioxidant alpha-lipoic acid improves endothelial dysfunction induced by acute hyperglycaemia during OGTT in impaired glucose tolerance.
    Xiang GD; Sun HL; Zhao LS; Hou J; Yue L; Xu L
    Clin Endocrinol (Oxf); 2008 May; 68(5):716-23. PubMed ID: 18070144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular K(ATP) channel blockade by glibenclamide, but not by acarbose, in patients with Type II diabetes.
    Abbink EJ; Pickkers P; van Rosendaal AJ; Lutterman JA; Tack CJ; Russel FG; Smits P
    Clin Sci (Lond); 2002 Mar; 102(3):307-14. PubMed ID: 11869171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.